Dernière mise à jour :
26/03/2024
Anticancéreux   Methotrexate sodium  
Injectable
Stabilité des solutions Stabilité en mélange Facteur influençant la stabilité Compatibilités Voie d’administration Bibliographie Pdf
   Structure chimique  

Noms commerciaux   Noms commerciaux     

Les noms commerciaux sont donnés à titre indicatif et la composition en excipients peut être différente selon les pays et selon les laboratoires

Abitrexate Afrique du sud
Antifolan Roumanie
Artrait Argentine
Bendatrexat Allemagne
Biometrox Brésil
Ebetrex Suisse
Ebetrexate Autriche
Emthexat Turquie
Emthexate Afrique du sud, Belgique, Espagne, Pays bas
Ledertrexate Belgique, France, Luxembourg, Maroc
Maxtrex Grande Bretagne
Metex Allemagne, Norvège
Methoblastin Afrique du sud
Methotrexamed Allemagne
Methotrexate France
Metoject Chili, Danemark, Espagne, Finlande, France, Grande Bretagne, Pays bas, Suède, Suisse
Metotrexato Chili
Trexan Finlande
Trexat Allemagne
Bibliographie   Injectable   Bibliographie : Methotrexate sodium  
Type Source
3 Revue Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
31 Revue Zhang Y, Xu QA, Trissel LA, Gilbert DL.
Physical and chemical stability of methotrexate sodium, cytarabine, and hydrocortisone sodium succinate in Elliott’s B solution.
Hosp Pharm 1996 ; 31: 965-970.
57 Revue Mayron D, Gennaro AR.
Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs.
Am J Health-Syst Pharm 1996 ; 53: 294-304.
81 Revue Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 Revue Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
85 Revue Trissel LA, Bready BB.
Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 1716-1719.
91 Revue Lober CA, Dollard PA.
Visual compatibility of gallium nitrate with selected drugs during Y-site injection.
Am J Hosp Pharm 1993 ; 50: 1208-1210.
99 Revue Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
110 Revue Vincke BJ, Verstraeten AE, El Eini DID, Mc Carthy TM.
Extended stability of 5-fluorouracil and methotrexate solutions in PVC containers.
Int J Pharm 1989 ; 54: 181-189.
145 Revue Lorillon P, Corbel JC, Mordelet MF, Basle B, Guesnier LR.
Photosensibility of 5-fluorouracile and methotrexate in translucent or opaque perfusers.
J Pharm Clin 1992 ; 11: 285-295.
150 Revue Aujoulat P, Coze C, Braguer D, Raybaud C.
Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens.
J Pharm Clin 1993 ; 12: 31-35.
162 Revue Benaji B, Dine T, Goudaliez F, Luyckx M, Brunet C, Mallevais ML, Gressier B, Cazin M, Cazin JC.
Compatibility study of methotrexate with PVC bags after repackaging into two types of infusion admixtures.
Int J Pharm 1994 ; 105: 83-87.
169 Revue Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
184 Revue Stewart JT, Warren FW, King DT, Fox JL.
Stability of ondansetron hydrochloride and five antineoplasic medications.
Am J Health-Syst Pharm 1996 ; 53: 1297-1300.
244 Revue Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249 Revue Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 Revue Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
300 Revue Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 Revue Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307 Revue Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
331 Revue Marquardt ED.
Visual compatibility of hydroxyzine hydrochloride with various antineoplasic agents.
Am J Hosp Pharm 1988 ; 45: 2127.
334 Revue Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 Revue Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
431 Revue McRae MP, King JC.
Compatibility of antineoplastic, antibiotic and corticosteroid drugs in intravenous admixtures.
Am J Hosp Pharm 1975 ; 33: 1010-1013.
491 Revue Turowski RC, Durthaler JM.
Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2181-2184.
492 Revue Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
739 Revue Cradock JC, Kleinmann LM, Rahman A.
Evaluation of some pharmaceutical aspects of intrathecal methotrexate sodium, cytarabine and hydrocortisone sodium succinate.
Am J Hosp Pharm 1978 ; 35: 402-406.
763 Revue Cohen MH, Jonhson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH.
Drug precipitation within IV tubing : A potential hazard of chemotherapy administration.
Cancer Treat Rep 1985 ; 69: 1325-1326.
859 Revue Karlsen J, Thonnesen HH, Olsen IR, Sollien AH, Skobba TJ.
Stability of cytotoxic intravenous solutions subjected to freeze-thaw treatment.
Nor Pharm Acta 1983 ; 45: 61-67.
905 Revue Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921 Revue Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
978 Revue Dick DM, Woloschuk DMM.
Methotrexate and cytarabine for intrathecal administration.
Can J Hosp Pharm 1994 ; 47: 147.
1021 Revue Dyvik O, Grislingaas AL, Tonnesen HH, Karlsen J.
Methotrexate in solutions - A stability test for the hospital pharmacy.
J Clin Hosp Pharm 1986 ; 11: 343-348.
1028 Revue Cheung YW, Vishnuvajjala BR, Flora KP.
Stability of cytarabine, methotrexate sodium, and hydrocortisone sodium succinate admixtures.
Am J Hosp Pharm 1984 ; 41: 1802-1806.
1088 Revue Johnston A, McKenzie MA, Krasnow SH, Hood MA, Cohen MH.
Drug trapping in intravenous infusion side arms.
JAMA 1984 ; 252: 2392.
1155 Revue Wright MP, Newton JM.
Stability of methotrexate injection in prefilled plastic disposable syringes.
Int J Pharm 1988 ; 45: 237-244.
1158 Revue McElnay JC, Elliott DS, Cartwright-Shamoon J, D?Arcy PF.
Stability of methotrexate and vinblastine in burette administration sets.
Int J Pharm 1988 ; 47: 239-247.
1410 Revue Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 Revue Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 Revue Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1469 Revue Jacolot A, Arnaud P, Lecompte D, Alamercery S, Caroff E, Naveau C, Guillot T, Bousselet M, Brion F.
Stability and compatibility of 2.5 mg/ml methotrexate solution in plastic syringes over 7 days.
Int J Pharm 1996 ; 128: 283-286.
1501 Revue Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M.
Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials.
Int J Pharm 1999 ; 185: 113-121.
1520 Laboratoire Etude de stabilité des médicaments en Ecoflac®
B Braun 2001
1625 Revue Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1661 Revue Trissel LA, King KM, Zhang Y, Wood AM.
Physical and chemical stability of methotrexate, cytarabine, and hydrocortisone in Elliott’s B Solution for intrathecal use.
J Oncol Pharm Practice 2002 ; 8: 27-32.
1662 Revue Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1925 Revue Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
2262 Revue Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3275 Revue D'Hondt M, Vangheluwe E, Van Dorpe S, Boonen J, Bauters T, Pelfrene B, Vandenbroucke J, Robays H, De Spiegeleer B
Stability of extemporaneously prepared cytarabine, methotrexate sodium, and methylprednisolone sodium succinate
Am J Health-Syst Pharm 2012 ; 69: 232-240.
3474 Laboratoire Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009
3580 Laboratoire Cytarabine Accord - Résumé des caractéristiques du produit
Accord Healthcare France 2016
3637 Laboratoire Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics
Hameln Pharmaceuticals 2014
3670 Revue Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30.
3731 Revue Chatterji D.C, Gallelli J.F.
Thermal and photolytic decomposition of methotrexate in aqueous solutions.
J Pharm Sci 1978 ; 67, 4: 526-530.
3980 Revue Nissen K.B, Jorgensen L.B, Berg D.L, Andersen G.
Stability study of methotrexate in 0.9% sodium chloride injection and 5% dextrose injection with limit tests for impurities.
Am J Health-Syst Pharm 2017 ; 74,9: e211-e223
4154 Laboratoire Bleomycin sulfate- Summary of Product Characteristics
Accord Health Care 2018
4578 Thèse Respaud R.
Etude de stabilité de médicaments anticancéreux injectables : apports analytiques et pharmaceutiques
2011
4641 Revue Zanon D, Selmin F, Centin G, Maximova N, Casiraghi A, Minghetti P.
Stability of high concentrated triple intrathecal therapy for pediatrics and mitigation strategies.
Eur J Pharm Sci 2021 ;167: 106039.

  Mentions Légales